Logo image of ALNY

ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Fundamental Analysis

NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock - Currency: USD

320.53  -4.16 (-1.28%)

After market: 320.53 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ALNY. ALNY was compared to 558 industry peers in the Biotechnology industry. ALNY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALNY shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ALNY has reported negative net income.
ALNY had a negative operating cash flow in the past year.
In the past 5 years ALNY always reported negative net income.
In the past 5 years ALNY reported 4 times negative operating cash flow.
ALNY Yearly Net Income VS EBIT VS OCF VS FCFALNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M -1B

1.2 Ratios

Looking at the Return On Assets, with a value of -6.40%, ALNY belongs to the top of the industry, outperforming 86.74% of the companies in the same industry.
ALNY's Return On Equity of -233.64% is on the low side compared to the rest of the industry. ALNY is outperformed by 69.18% of its industry peers.
Industry RankSector Rank
ROA -6.4%
ROE -233.64%
ROIC N/A
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALNY Yearly ROA, ROE, ROICALNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600

1.3 Margins

ALNY has a Gross Margin of 86.01%. This is amongst the best in the industry. ALNY outperforms 89.25% of its industry peers.
In the last couple of years the Gross Margin of ALNY has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ALNY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
ALNY Yearly Profit, Operating, Gross MarginsALNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

ALNY does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALNY has more shares outstanding than it did 1 year ago.
ALNY has more shares outstanding than it did 5 years ago.
ALNY has a better debt/assets ratio than last year.
ALNY Yearly Shares OutstandingALNY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ALNY Yearly Total Debt VS Total AssetsALNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

An Altman-Z score of 4.85 indicates that ALNY is not in any danger for bankruptcy at the moment.
ALNY has a better Altman-Z score (4.85) than 77.24% of its industry peers.
A Debt/Equity ratio of 8.88 is on the high side and indicates that ALNY has dependencies on debt financing.
ALNY has a Debt to Equity ratio of 8.88. This is amonst the worse of the industry: ALNY underperforms 83.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 8.88
Debt/FCF N/A
Altman-Z 4.85
ROIC/WACCN/A
WACC9.7%
ALNY Yearly LT Debt VS Equity VS FCFALNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 3.04 indicates that ALNY has no problem at all paying its short term obligations.
ALNY's Current ratio of 3.04 is on the low side compared to the rest of the industry. ALNY is outperformed by 64.16% of its industry peers.
ALNY has a Quick Ratio of 2.98. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.98, ALNY is not doing good in the industry: 63.44% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 2.98
ALNY Yearly Current Assets VS Current LiabilitesALNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.01% over the past year.
ALNY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.21%.
Measured over the past years, ALNY shows a very strong growth in Revenue. The Revenue has been growing by 59.21% on average per year.
EPS 1Y (TTM)22.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.38%
Revenue 1Y (TTM)17.21%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%20.2%

3.2 Future

ALNY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 62.06% yearly.
The Revenue is expected to grow by 28.14% on average over the next years. This is a very strong growth
EPS Next Y36.07%
EPS Next 2Y63.67%
EPS Next 3Y70.23%
EPS Next 5Y62.06%
Revenue Next Year30.82%
Revenue Next 2Y31.16%
Revenue Next 3Y29.69%
Revenue Next 5Y28.14%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALNY Yearly Revenue VS EstimatesALNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ALNY Yearly EPS VS EstimatesALNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ALNY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 217.62, ALNY can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ALNY is valued cheaper than 87.46% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.44. ALNY is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 217.62
ALNY Price Earnings VS Forward Price EarningsALNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 -100 200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALNY Per share dataALNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as ALNY's earnings are expected to grow with 70.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y63.67%
EPS Next 3Y70.23%

More info and screens

0

5. Dividend

5.1 Amount

ALNY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALNYLAM PHARMACEUTICALS INC

NASDAQ:ALNY (7/18/2025, 8:00:01 PM)

After market: 320.53 0 (0%)

320.53

-4.16 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners97.14%
Inst Owner Change0.01%
Ins Owners0.19%
Ins Owner Change4.59%
Market Cap41.79B
Analysts78.46
Price Target332.12 (3.62%)
Short Float %2.66%
Short Ratio3.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.04%
Min EPS beat(2)-2.21%
Max EPS beat(2)58.28%
EPS beat(4)3
Avg EPS beat(4)37.07%
Min EPS beat(4)-2.21%
Max EPS beat(4)88.19%
EPS beat(8)6
Avg EPS beat(8)43.72%
EPS beat(12)8
Avg EPS beat(12)24.57%
EPS beat(16)9
Avg EPS beat(16)15.65%
Revenue beat(2)0
Avg Revenue beat(2)-0.47%
Min Revenue beat(2)-0.56%
Max Revenue beat(2)-0.39%
Revenue beat(4)1
Avg Revenue beat(4)9.21%
Min Revenue beat(4)-7.88%
Max Revenue beat(4)45.66%
Revenue beat(8)3
Avg Revenue beat(8)16.07%
Revenue beat(12)5
Avg Revenue beat(12)9.06%
Revenue beat(16)7
Avg Revenue beat(16)6.21%
PT rev (1m)0.54%
PT rev (3m)2.34%
EPS NQ rev (1m)-3.16%
EPS NQ rev (3m)14.45%
EPS NY rev (1m)16.81%
EPS NY rev (3m)19.03%
Revenue NQ rev (1m)1.31%
Revenue NQ rev (3m)1.02%
Revenue NY rev (1m)1.88%
Revenue NY rev (3m)1.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 217.62
P/S 17.8
P/FCF N/A
P/OCF N/A
P/B 362.06
P/tB 362.06
EV/EBITDA N/A
EPS(TTM)-2.09
EYN/A
EPS(NY)1.47
Fwd EY0.46%
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS18.01
BVpS0.89
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.4%
ROE -233.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.01%
FCFM N/A
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 8.88
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.6%
Cap/Sales 1.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.04
Quick Ratio 2.98
Altman-Z 4.85
F-Score5
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)112.53%
Cap/Depr(5y)140.08%
Cap/Sales(3y)3.96%
Cap/Sales(5y)7.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.38%
EPS Next Y36.07%
EPS Next 2Y63.67%
EPS Next 3Y70.23%
EPS Next 5Y62.06%
Revenue 1Y (TTM)17.21%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%20.2%
Revenue Next Year30.82%
Revenue Next 2Y31.16%
Revenue Next 3Y29.69%
Revenue Next 5Y28.14%
EBIT growth 1Y34.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year230.75%
EBIT Next 3Y137.52%
EBIT Next 5Y132.55%
FCF growth 1Y87.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y91.59%
OCF growth 3YN/A
OCF growth 5YN/A